	US 12,319,720 B2
	Neoantigen vaccines for triple negative breast cancer
William Gillanders, St. Louis, MO (US); Ted Hansen, North Potomac, MD (US); and S. Peter Goedegebuure, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by Washington University, St. Louis, MO (US)
Filed on Aug. 31, 2022, as Appl. No. 17/823,937.
Claims priority of provisional application 63/239,312, filed on Aug. 31, 2021.
Prior Publication US 2023/0145121 A1, May 11, 2023
Int. Cl. C07K 14/47 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 15/85 (2006.01)

CPC C07K 14/4748 (2013.01) [A61P 35/00 (2018.01); C07K 14/47 (2013.01); C12N 15/85 (2013.01); A61K 39/00 (2013.01); C07K 2319/00 (2013.01); C12N 2800/107 (2013.01)]

4 Claims

4. A method of treating Triple Negative Breast Cancer (TNBC) in an individual, the method comprising administering a therapeutically effective amount of a fusion protein, comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein, wherein the at least one TNBC-associated neoantigen epitope is LRRC27, and wherein the mutant ubiquitin protein is selected from SEQ ID NO: 1, SEQ ID NO: 1 comprising substitution of a leucine at position 76, and SEQ ID NO: 1 comprising substitution of an isoleucine at position 76.